Pharma BD Deal Intelligence
Bristol Myers Squibb announced an $800 million upfront agreement with SystImmune for BL-B01D1, continuing the pharmaceutical industry momentum in antibody-drug…
Bristol-Myers Squibb is paying $800 million upfront for rights to a HER3-directed ADC from China's SystImmune in a deal that could swell to $8.4 billion.
Bristol Myers Squibb and SystImmune entered a global ADC collaboration worth potentially up to $8.4 billion for the development and commercialization of…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Bristol-Myers Squibb entered an exclusive global license and collaboration agreement with SystImmune for BL-B01D1, a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate. BMS paid $800 million upfront with up to $500 million in contingent near-term payments and an additional $7.1 billion in development, regulatory, and sales milestones. SystImmune retained rights in Mainland China; BMS gained ex-China development and commercialization rights.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / SystImmune Inc. (this deal) | 2023 | $8.4B | 71 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / Turning Point Therapeutics Inc. | 2022 | $4.1B | 70 |
← Browse all deals · How we score deals
More: 2023 deals · Bristol-Myers Squibb Company deals · Oncology deals